How can biomaterial-conjugated antimicrobial peptides fight bacteria and be protected from degradation?
Source abstract
Abstract
The emergence of antibiotic-resistant bacteria is a serious threat to public health. Antimicrobial peptides (AMP) are a powerful alternative to antibiotics due to their low propensity to induce bacterial resistance. However, cytotoxicity and short half-lives have limited their clinical translation. To overcome these problems, AMP conjugation has gained relevance in the biomaterials field. Nevertheless, few studies describe the influence of conjugation on enzymatic protection, mechanism of action and antimicrobial efficacy. This review addresses this gap by providing a detailed comparison between conjugated and soluble AMP. Additionally, commonly employed chemical reactions and factors to consider when promoting AMP conjugation are reviewed. The overall results suggested that AMP conjugated onto biomaterials are specifically protected from degradation by trypsin and/or pepsin. However, sometimes, their antimicrobial efficacy was reduced. Due to limited conformational freedom in conjugated AMP, compared to their soluble forms, they appear to act initially by creating small protuberances on bacterial membranes that may lead to the alteration of membrane potential and/or formation of holes, triggering cell death. Overall, AMP conjugation onto biomaterials is a promising strategy to fight infection, particularly associated to the use of medical devices. Nonetheless, some details need to be addressed before conjugated AMP reach clinical practice. STATEMENT OF SIGNIFICANCE: Covalent conjugation of antimicrobial peptides (AMP) has been one of the most widely used strategies by bioengineers, in an attempt to not only protect AMP from proteolytic degradation, but also to prolong their residence time at the target tissue. However, an explanation for the mode of action of conjugated AMP is still lacking. This review extensively gathers works on AMP conjugation and puts forward a mechanism of action for AMP when conjugated onto biomaterials. The implications of AMP conjugation on antimicrobial activity, cytotoxicity and resistance to proteases are all discussed. A thorough review of commonly employed chemical reactions for this conjugation is also provided. Finally, details that need to be addressed for conjugated AMP to reach clinical practice are discussed.
Source: europepmc · Quality: candidate unverified · Source record ↗
Research context
OpenAlex topics: Antimicrobial Peptides and Activities · Antimicrobial agents and applications · Polydiacetylene-based materials and applications
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (100+)
Show source-provided references
1. The science of antibiotic discovery10.1016/j.cell.2020.02.056 ↗
2. The antibiotic resistance crisis: part 1: causes and threats
3. Discovery, research, and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosis10.1016/S1473-3099(17)30753-3 ↗
4. Prioritization of pathogens to guide discovery, research and development of new antibiotics for drug-resistant bacterial infections, including tuberculosis, (n.d.). https://www.who.int/publications/i/item/WHO-EMP-IAU-2017.12 (accessed November 4, 2023).
5. Interaction of cationic peptides with lipoteichoic acid and gram- positive bacteria10.1128/IAI.67.12.6445-6453.1999 ↗
6. Biological properties of structurally related α-helical cationic antimicrobial peptides10.1128/IAI.67.4.2005-2009.1999 ↗
7. Global analysis of the yeast lipidome by quantitative shotgun mass spectrometry10.1073/pnas.0811700106 ↗
8. Comparative lipidomics of azole sensitive and resistant clinical isolates of candida albicans reveals unexpected diversity in molecular lipid imprints10.1371/journal.pone.0019266 ↗
9. Membrane active antimicrobial peptides: translating mechanistic insights to design10.3389/fnins.2017.00073 ↗
10. The bacterial cell envelope10.1101/cshperspect.a000414 ↗
11. Molecular Architecture and charging effects enhance the in vitro and in vivo performance of multi-arm antimicrobial agents based on star-shaped poly(l-lysine)
12. Photodynamic therapy: a special emphasis on nanocarrier-mediated delivery of photosensitizers in antimicrobial therapy10.1016/j.arabjc.2023.104583 ↗
13. Genetics of antimicrobial resistance10.1080/10495390600957092 ↗
14. Molecular engineering of antimicrobial peptide (AMP)-polymer conjugates10.1039/D1BM00423A ↗
15. Emr, an Escherichia coli locus for multidrug resistance10.1073/pnas.89.19.8938 ↗
16. The challenge of efflux-mediated antibiotic resistance in Gram-negative bacteria10.1128/CMR.00117-14 ↗
17. Analytical challenges of microbial biofilms on medical devices10.1021/ac2029997 ↗
18. Estimating health care-associated infections and deaths in U.S. hospitals10.1177/003335490712200205 ↗
19. Bacterial biofilms: a common cause of persistent infections10.1126/science.284.5418.1318 ↗
20. Riddle of biofilm resistance10.1128/AAC.45.4.999-1007.2001 ↗
21. Skin wound healing: an update on the current knowledge and concepts10.1159/000454919 ↗
22. Strategies for antimicrobial peptide coatings on medical devices: a review and regulatory science perspective10.1080/07388551.2020.1828810 ↗
23. Chronic wounds and the medical biofilm paradigm10.12968/jowc.2010.19.2.46966 ↗
24. Antimicrobial resistance three ways: healthcare crisis, major concepts and the relevance of biofilms10.1093/femsec/fiz115 ↗
25. Smart biomaterial-based systems for intrinsic stimuli-responsive chronic wound management
26. Amphibian antimicrobial peptides and Protozoa: lessons from parasites10.1016/j.bbamem.2008.11.002 ↗
27. A Review of Antimicrobial Peptides and Their Therapeutic Potential as Anti-Infective Drugs10.1080/02713680590968637 ↗
28. Antimicrobial peptides: general overview and clinical implications in human health and disease10.1016/j.clim.2009.12.004 ↗
29. Antimicrobial activity and stability to proteolysis of small linear cationic peptides with D-amino acid substitutions10.1111/j.1348-0421.2002.tb02759.x ↗
30. Antimicrobial and host-defense peptides as new anti-infective therapeutic strategies10.1038/nbt1267 ↗
31. Designing antimicrobial peptides: form follows function
32. Recent advances in the design of antimicrobial peptide conjugates10.1039/D1TB02757C ↗
33. Antimicrobial peptides: promising alternatives in the post feeding antibiotic era10.1002/med.21542 ↗
34. The value of antimicrobial peptides in the age of resistance10.1016/S1473-3099(20)30327-3 ↗
35. Antimicrobial peptide-based materials: opportunities and challenges10.1039/D1TB02617H ↗
36. Antimicrobial peptides: linking partition, activity and high membrane-bound concentrations10.1038/nrmicro2095 ↗
37. Antimicrobial peptides: classification, design, application and research progress in multiple fields10.3389/fmicb.2020.582779 ↗
38. Design, optimization, and nanotechnology of antimicrobial peptides: From exploration to applications10.1016/j.nantod.2021.101229 ↗
39. Antimicrobial peptides: pore formers or metabolic inhibitors in bacteria?10.1038/nrmicro1098 ↗
40. Antimicrobial peptides10.1016/j.cub.2015.11.017 ↗
41. The multifaceted nature of antimicrobial peptides: current synthetic chemistry approaches and future directions10.1039/D0CS00729C ↗
42. Mechanisms of antimicrobial peptide action and resistance10.1124/pr.55.1.2 ↗
43. The expanding scope of antimicrobial peptide structures and their modes of action10.1016/j.tibtech.2011.05.001 ↗
44. Tethering antimicrobial peptides: current status and potential challenges10.1016/j.biotechadv.2010.08.012 ↗
45. Antimicrobial peptides: an alternative for innovative medicines?10.1007/s00253-015-6375-x ↗
46. Antimicrobial peptides: their role as infection-selective tracers for molecular imaging10.1155/2014/867381 ↗
47. Antimicrobial peptides of multicellular organisms10.1038/415389a ↗
48. H. Sun, Y. Hong, Y. Xi, Y. Zou, J. Gao, J. Du, Synthesis, self-assembly, and biomedical applications of antimicrobial peptide-polymer conjugates, Biomacromolecules. 19 (2018) 1701–1720. https://doi.org/10.1021/acs.biomac.8b00208.10.1021/acs.biomac.8b00208 ↗
49. Peptides and peptidomimetics for antimicrobial drug design10.3390/ph8030366 ↗
50. Biological activity and structural aspects of PGLa interaction with membrane mimetic systems10.1016/j.bbamem.2009.05.012 ↗
51. An antimicrobial peptide, magainin 2, induced rapid flip-flop of phospholipids coupled with pore formation and peptide translocation10.1021/bi960016v ↗
52. Translocation of a channel-forming antimicrobial peptide, magainin 2, across lipid bilayers by forming a pore10.1021/bi00019a033 ↗
53. S.J. Ludtke, K. He, W.T. Heller, T.A. Harroun, L. Yang, H.W. Huang, Membrane pores induced by magainin, Biochemistry. 35 (1996) 13723–13728. https://doi.org/10.1021/BI9620621/ASSET/IMAGES/LARGE/BI9620621F00005.JPEG.10.1021/bi9620621 ↗
54. Mode of action of linear amphipathic-helical antimicrobial peptides10.1002/(SICI)1097-0282(1998)47:6<451::AID-BIP4>3.0.CO;2-F ↗
55. Damage of the bacterial cell envelope by antimicrobial peptides gramicidin S and PGLa as revealed by transmission and scanning electron microscopy10.1128/AAC.00124-10 ↗
56. Tryptophan- and arginine-rich antimicrobial peptides: structures and mechanisms of action10.1016/j.bbamem.2006.04.006 ↗
57. Structural determinants of host defense peptides for antimicrobial activity and target cell selectivity10.1016/j.biochi.2010.02.023 ↗
58. Mode of action of membrane active antimicrobial peptides10.1002/bip.10260 ↗
59. Therapeutic peptides: new arsenal against drug resistant pathogens10.2174/13816128113199990011 ↗
60. Therapeutic potential of host defense peptides in antibiotic-resistant infections10.2174/138161212799277617 ↗
61. Multifunctional host defense peptides: intracellular-targeting antimicrobial peptides10.1111/j.1742-4658.2009.07359.x ↗
62. PEGylation of the peptide Bac7(1-35) reduces renal clearance while retaining antibacterial activity and bacterial cell penetration capacity10.1016/j.ejmech.2015.03.028 ↗
63. Integrating in vitro and in silico analysis of a cationic antimicrobial peptide interaction with model membranes of colistin-resistant Pseudomonas aeruginosa strains10.3390/pharmaceutics14061248 ↗
64. Antimicrobial peptides: an emerging category of therapeutic agents10.3389/fcimb.2016.00194 ↗
65. AMPed up immunity: how antimicrobial peptides have multiple roles in immune defense10.1016/j.it.2008.12.003 ↗
66. In Silico identification of antimicrobial peptides in the proteomes of goat and sheep milk and feta cheese10.3390/proteomes7040032 ↗
67. Nanostructured antimicrobial peptides: the last push towards clinics10.1016/j.biotechadv.2020.107603 ↗
68. Antimicrobial peptide shows enhanced activity and reduced toxicity upon grafting to chitosan polymers10.1039/C5CC04010H ↗
69. Multivalent antimicrobial peptides as therapeutics: design principles and structural diversities10.1007/s10989-010-9230-z ↗
70. Antimicrobial peptides under clinical investigation10.1002/pep2.24122 ↗
71. Topical antimicrobial peptide formulations for wound healing: current developments and future prospects10.1016/j.actbio.2019.12.025 ↗
72. D.B. Graham, J. Tripp, Ofloxacin. [Updated 2023 Jun 26]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK549837/.
73. Antimicrobial peptides (AMPs) as drug candidates: a patent review (2003–2015)10.1080/13543776.2016.1176149 ↗
74. Antimicrobial peptides under clinical trials10.2174/1568026616666160713143331 ↗
75. An overview of antimicrobial peptides and the latest advances in their development10.1080/14712598.2017.1315402 ↗
76. Review: lessons learned from clinical trials using antimicrobial peptides (AMPs)10.3389/fmicb.2021.616979 ↗
77. Inhibitory effects and mechanisms of physiological conditions on the activity of enantiomeric forms of an α-helical antibacterial peptide against bacteria10.1016/j.peptides.2011.05.023 ↗
78. Easy strategy to increase salt resistance of antimicrobial peptides10.1128/AAC.00202-11 ↗
79. Divalent cations modulate membrane binding and pore formation of a potent antibiotic peptide analog of alamethicin10.1016/j.ceca.2012.11.012 ↗
80. Short symmetric-end antimicrobial peptides centered on β-turn amino acids unit improve selectivity and stability10.3389/fmicb.2018.02832 ↗
81. Design and membrane-disruption mechanism of charge-enriched AMPs exhibiting cell selectivity, high-salt resistance, and anti-biofilm properties10.1007/s00726-015-2104-0 ↗
82. Facile preparation of phospholipid–amorphous calcium carbonate hybrid nanoparticles: toward controllable burst drug release and enhanced tumor penetration10.1039/C8CC07694D ↗
83. A novel tool against multiresistant bacterial pathogens: lipopeptide modification of the natural antimicrobial peptide ranalexin for enhanced antimicrobial activity and improved pharmacokinetics10.1016/j.ijantimicag.2018.03.023 ↗
84. Strategies employed in the design and optimization of synthetic antimicrobial peptide amphiphiles with enhanced therapeutic potentials10.1016/j.addr.2014.10.013 ↗
85. Antifungal and antibiofilm activities and the mechanism of action of repeating lysine-tryptophan peptides against Candida albicans10.3390/microorganisms8050758 ↗
86. Activity of the de novo engineered antimicrobial peptide WLBU2 against Pseudomonas aeruginosa in human serum and whole blood: implications for systemic applications10.1128/AAC.49.8.3208-3216.2005 ↗
87. Antimicrobial peptides with high proteolytic resistance for combating gram-negative bacteria10.1021/acs.jmedchem.8b01348 ↗
88. Inspiration from the mirror: d-amino acid containing peptides in biomedical approaches10.1515/bmc-2015-0035 ↗
89. D- and unnatural amino acid substituted antimicrobial peptides with improved proteolytic resistance and their proteolytic degradation characteristics10.3389/fmicb.2020.563030 ↗
90. Cyclic mu-opioid receptor ligands containing multiple N-methylated amino acid residues10.1016/j.bmcl.2017.03.016 ↗
91. Chemically modified and conjugated antimicrobial peptides against superbugs10.1039/D0CS01026J ↗
92. Characterization of tachyplesin peptides and their cyclized analogues to improve antimicrobial and anticancer properties10.3390/ijms20174184 ↗
93. Click chemistry for cyclic peptide drug design10.1007/978-1-4939-9504-2_8 ↗
94. Modification of proteins using olefin metathesis10.1039/C9QM00494G ↗
95. The effect of lipidation and glycosylation on short cationic antimicrobial peptides10.1016/j.bbamem.2020.183195 ↗
96. Lipidation of antimicrobial peptides as a design strategy for future alternatives to antibiotics10.3390/ijms21249692 ↗
97. Advances on chemically modified antimicrobial peptides for generating peptide antibiotics10.1039/D1CC03793E ↗
98. Glycosylation and lipidation strategies: approaches for improving antimicrobial peptide efficacy
99. The importance of the glycosylation of antimicrobial peptides: natural and synthetic approaches10.1016/j.drudis.2017.02.001 ↗
100. Cysteine S-glycosylation, a new post-translational modification found in glycopeptide bacteriocins10.1016/j.febslet.2011.01.023 ↗